- Home
- Publications
- Publication Search
- Publication Details
Title
DYRK1A inhibition as potential treatment for Alzheimer’s disease
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 8, Issue 6, Pages 681-696
Publisher
Future Science, LTD
Online
2016-04-14
DOI
10.4155/fmc-2016-0013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis
- (2015) So Masaki et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents
- (2015) Rammohan R. Yadav et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
- (2015) Ulli Rothweiler et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice
- (2015) Gaëlle Naert et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- 10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A
- (2015) Hannes Falke et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologiesin vitro
- (2015) Séverine Coutadeur et al. JOURNAL OF NEUROCHEMISTRY
- DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications
- (2015) Ramzi Abbassi et al. PHARMACOLOGY & THERAPEUTICS
- Unprecedented One-Pot Chemocontrolled Entry to Thioxoimidazolidinones and Aminoimidazolones: Synthesis of Kinase Inhibitor Leucettamine B
- (2015) Manikandan Selvaraju et al. ACS Combinatorial Science
- Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ
- (2015) Rie Sonamoto et al. Scientific Reports
- Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors
- (2015) Katharina Rüben et al. PLoS One
- First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer’s Disease
- (2014) Marica Mariano et al. ACS Chemical Neuroscience
- Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors
- (2014) Binia Drung et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors
- (2014) Amélie Bruel et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
- (2014) Walter Becker et al. CNS & Neurological Disorders-Drug Targets
- Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors
- (2014) Oussama Dehbi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of Potent DFG-in Inhibitors of Platelet Derived Growth Factor Receptorβ (PDGF-Rβ) Guided by Water Thermodynamics
- (2014) Rebecca Horbert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acridone Alkaloids from Glycosmis chlorosperma as DYRK1A Inhibitors
- (2014) Mehdi A. Beniddir et al. JOURNAL OF NATURAL PRODUCTS
- Chemistry: Chemical con artists foil drug discovery
- (2014) Jonathan Baell et al. NATURE
- Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors
- (2014) Christian Schmitt et al. PLoS One
- Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4
- (2014) Christian Schmitt et al. ACS Medicinal Chemistry Letters
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
- (2013) Parminder Raina et al. ANNALS OF INTERNAL MEDICINE
- Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315
- (2013) Thomas C. Coombs et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
- (2013) Kevin Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Kinase Inhibitors of Marine Origin
- (2013) Sandip B. Bharate et al. CHEMICAL REVIEWS
- Systematic Exploration of Natural and Synthetic Flavonoids for the Inhibition of Staphylococcus aureus Biofilms
- (2013) Suvi Manner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition
- (2013) Kenyu Yoshida et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity
- (2013) Stéphanie Gourdain et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
- (2013) Rafael De la Torre et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Synthesis of Oxindole-Based Bioorganometallic Kinase Inhibitors Incorporating One or More Ferrocene Groups
- (2013) Jahangir Amin et al. ORGANOMETALLICS
- Recent developments of protein kinase inhibitors as potential AD therapeutics
- (2013) Volkmar Tell et al. Frontiers in Cellular Neuroscience
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
- (2013) Anja Mähler et al. EPMA Journal
- Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?
- (2012) Breland Smith et al. ACS Chemical Neuroscience
- Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors
- (2012) Gregory D. Cuny et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide
- (2012) Sébastien Deslandes et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues : A novel DYRK1A inhibitor class
- (2012) Cleopatra Neagoie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases
- (2012) Yvonnick Loidreau et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, Biological Evaluation, and Molecular Modeling of Natural and Unnatural Flavonoidal Alkaloids, Inhibitors of Kinases
- (2012) Thanh Binh Nguyen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
- (2012) Tania Tahtouh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases
- (2012) Vassilios Myrianthopoulos et al. ACS Medicinal Chemistry Letters
- Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease
- (2011) Patrizia Mecocci et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)
- (2011) Andrew S. Rosenthal et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1
- (2011) Joong-Kyu Park et al. BMB Reports
- Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A
- (2011) Stefania Sarno et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- p53 downregulates Down syndrome-associated DYRK1A through miR-1246
- (2011) Yu Zhang et al. EMBO REPORTS
- Recent advances in understanding the antibacterial properties of flavonoids
- (2011) T.P. Tim Cushnie et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Regulation of RCAN1 Protein Activity by Dyrk1A Protein-mediated Phosphorylation
- (2011) Min-Su Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives
- (2011) Francis Giraud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing
- (2011) Mansour Debdab et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors
- (2010) J. Reniers et al. BIOORGANIC & MEDICINAL CHEMISTRY
- High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation
- (2010) David O Azorsa et al. BMC GENOMICS
- DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles
- (2010) Sergi Aranda et al. FASEB JOURNAL
- MNB/DYRK1A as a multiple regulator of neuronal development
- (2010) Francisco J. Tejedor et al. FEBS Journal
- Activation, regulation, and inhibition of DYRK1A
- (2010) Walter Becker et al. FEBS Journal
- The role of DYRK1A in neurodegenerative diseases
- (2010) Jerzy Wegiel et al. FEBS Journal
- Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer’s disease
- (2010) Young Shin Ryu et al. JOURNAL OF NEUROCHEMISTRY
- Halogenated Indole Alkaloids from Marine Invertebrates
- (2010) Patrícia Mendonça Pauletti et al. Marine Drugs
- Current Treatment and Recent Clinical Research in Alzheimer's Disease
- (2010) Judith Neugroschl et al. MOUNT SINAI JOURNAL OF MEDICINE
- The secretases: enzymes with therapeutic potential in Alzheimer disease
- (2010) Bart De Strooper et al. Nature Reviews Neurology
- Synthesis of two series of pyrazolic analogues of the marine alkaloids granulatimide and isogranulatimide as potent Checkpoint 1 kinase inhibitors
- (2010) Sébastien Deslandes et al. TETRAHEDRON LETTERS
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
- (2010) Yasushi Ogawa et al. Nature Communications
- Synthesis and kinase inhibitory activity of novel substituted indigoids
- (2009) Anne Beauchard et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins
- (2009) Rufine Akue-Gedu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors
- (2009) Kyung Ah Koo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)
- (2009) Bryan T. Mott et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Function and regulation of Dyrk1A: towards understanding Down syndrome
- (2009) Joongkyu Park et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles
- (2009) César Sánchez et al. CHEMICAL COMMUNICATIONS
- Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors
- (2009) Mansour Debdab et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation
- (2009) Nora Göckler et al. FEBS Journal
- An Efficient Method for the Preparation of New Analogs of Leucettamine B under Solvent-Free Microwave Irradiation
- (2009) François Carreaux et al. HETEROCYCLES
- Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease
- (2009) Volodymyr Samoylenko et al. JOURNAL OF ETHNOPHARMACOLOGY
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
- (2009) N Raje et al. LEUKEMIA
- Two New Peltogynoids fromAcacia niloticaDelile with Kinase Inhibitory Activity
- (2009) Augustine Ahmadu et al. PLANTA MEDICA
- Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
- (2009) Fayçal Guedj et al. PLoS One
- The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome
- (2008) Jerzy Wegiel et al. ACTA NEUROPATHOLOGICA
- In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives
- (2008) Emilie Rossignol et al. ANTI-CANCER DRUGS
- The selectivity of inhibitors of protein kinase CK2: an update
- (2008) Mario A. Pagano et al. BIOCHEMICAL JOURNAL
- Identification ofN,N-dimethyltryptamine andβ-carbolines in psychotropic ayahuasca beverage
- (2008) Cristiana Gambelunghe et al. BIOMEDICAL CHROMATOGRAPHY
- Cytotoxicity of the β-carboline alkaloids harmine and harmaline in human cell assays in vitro
- (2008) Judith Jiménez et al. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
- Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome
- (2008) Fei Liu et al. FASEB JOURNAL
- Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome
- (2008) Jianhua Shi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anticancer Alkaloid Lamellarins Inhibit Protein Kinases
- (2008) Dianne Baunbæk et al. Marine Drugs
- Flavonoids: Prospective Drug Candidates
- (2008) Luisa Cazarolli et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now